Autoregulation of cerebral blood flow in patients resuscitated from cardiac arrest

Citation
C. Sundgreen et al., Autoregulation of cerebral blood flow in patients resuscitated from cardiac arrest, STROKE, 32(1), 2001, pp. 128-132
Citations number
27
Categorie Soggetti
Neurology,"Cardiovascular & Hematology Research
Journal title
STROKE
ISSN journal
00392499 → ACNP
Volume
32
Issue
1
Year of publication
2001
Pages
128 - 132
Database
ISI
SICI code
0039-2499(200101)32:1<128:AOCBFI>2.0.ZU;2-H
Abstract
Background and Purpose-Under normal circumstances, autoregulation maintains cerebral blood flow (CBF) constant within a wide range of mean arterial pr essure (MAP). It remains unknown whether patients resuscitated from cardiac arrest have preserved CBF autoregulation. In this study, CBF autoregulatio n was investigated within the first 24 hours after resuscitation from cardi ac arrest. Methods-Eighteen patients and 6 healthy volunteers had relative changes in CBF determined by transcranial Doppler mean flow velocity (V-mean) in the m iddle cerebral artery during a stepwise rise in MAP by use of norepinephrin e infusion. V-mean was plotted against MAP, and a lower limit of autoregula tion was identified by double regression analysis based on the least-square s method. Results-In patients, V-mean increased from a median of 33 (range 19 to 73) to 37 (22 to 100) cm/s (P<0.001) during a norepinephrine-induced rise in MA P from 78 (46 to 118) to 106 (60 to 149) mm Hg. Eight of 18 patients had im paired CBF autoregulation, and in 5 of the 10 patients with preserved CBF a utoregulation, the lower limit of autoregulation could be identified. The l ower limit of CBF autoregulation was 76 mm Hg (41 to 105 mm Hg) in the volu nteers and 114 mm Hg (80 to 120 mm Hg) in the 5 patients with preserved aut oregulation (P<0.01). Conclusions-We conclude that in a majority of patients in the acute phase a fter cardiac arrest, cerebral autoregulation is either absent or right-shif ted. These results indicate that MAP should be kept at a higher level than commonly accepted to secure cerebral perfusion. We recommend, however, that further randomized clinical trials are performed to determine whether symp athomimetic drugs improve neurological outcome.